BR0016217A - Composto, processo para prepará-lo, composição farmacêutica, e, uso do composto - Google Patents

Composto, processo para prepará-lo, composição farmacêutica, e, uso do composto

Info

Publication number
BR0016217A
BR0016217A BR0016217-5A BR0016217A BR0016217A BR 0016217 A BR0016217 A BR 0016217A BR 0016217 A BR0016217 A BR 0016217A BR 0016217 A BR0016217 A BR 0016217A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
preparing
compounds
spacer
Prior art date
Application number
BR0016217-5A
Other languages
English (en)
Inventor
Constant Adriaan Anton Boeckel
Cornelia Maria Tromp
Tamara Theodora Maria Geertsen
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0016217A publication Critical patent/BR0016217A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSTO, PROCESSO PARA PREPARá-LO, COMPOSIçãO FARMACêUTICA, E, USO DO COMPOSTO". A presente invenção refere-se a compostos de fórmula (I): em que R é independentemente SO~ 3~ ou CH~ 3~; o espaçador é um espaçador flexível de um comprimento de 13 - 25 átomos; a carga do resíduo pentassacarídeo é compensada pelos contraíons positivamente carregados; e o número total de grupos sulfato do resíduo pentassacarídeo é 4,5 ou 6; ou um seu sal, prodroga ou solvato farmaceuticamente aceitável. Os compostos da invenção têm atividade anti-trombótica e podem ser usados no tratamento ou prevenção de doenças relacionadas com a trombina.
BR0016217-5A 1999-12-07 2000-12-01 Composto, processo para prepará-lo, composição farmacêutica, e, uso do composto BR0016217A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99204172 1999-12-07
PCT/EP2000/012155 WO2001042262A2 (en) 1999-12-07 2000-12-01 Antithrombotic compound

Publications (1)

Publication Number Publication Date
BR0016217A true BR0016217A (pt) 2002-09-10

Family

ID=8240976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016217-5A BR0016217A (pt) 1999-12-07 2000-12-01 Composto, processo para prepará-lo, composição farmacêutica, e, uso do composto

Country Status (23)

Country Link
US (1) US6875755B2 (pt)
EP (1) EP1237897B1 (pt)
JP (1) JP4820517B2 (pt)
KR (1) KR100776607B1 (pt)
CN (1) CN1195767C (pt)
AR (1) AR026726A1 (pt)
AU (1) AU781846B2 (pt)
BR (1) BR0016217A (pt)
CA (1) CA2393042C (pt)
CO (1) CO5251449A1 (pt)
CZ (1) CZ303385B6 (pt)
HK (1) HK1047593A1 (pt)
HU (1) HUP0203471A3 (pt)
IL (2) IL149628A0 (pt)
NO (1) NO323059B1 (pt)
NZ (1) NZ519100A (pt)
PE (1) PE20010935A1 (pt)
PL (1) PL202840B1 (pt)
RU (1) RU2266913C2 (pt)
SK (1) SK287682B6 (pt)
TW (1) TWI289566B (pt)
WO (1) WO2001042262A2 (pt)
ZA (1) ZA200203799B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002331426B2 (en) * 2001-09-07 2008-01-10 Dr. Reddy's Laboratories Sa Synthetic heparin pentasaccharides
JP4530852B2 (ja) 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
ATE370141T1 (de) 2002-10-07 2007-09-15 Merck & Co Inc Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
MXPA05004890A (es) * 2002-11-07 2005-07-22 Merck & Co Inc Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
WO2004064778A2 (en) 2003-01-17 2004-08-05 Merck & Co. Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7388019B2 (en) 2003-01-31 2008-06-17 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ATE447574T1 (de) 2003-05-14 2009-11-15 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
US7332520B2 (en) 2003-06-06 2008-02-19 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2004249163A1 (en) 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2004261186A1 (en) 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1574516A1 (en) * 2004-03-05 2005-09-14 Sanofi-Aventis Antithrombotic compound
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
MY145269A (en) * 2005-10-10 2012-01-13 Organon Nv Antithrombotic dual inhibitors comprising a biotin label
EP2512448B1 (en) 2009-12-18 2016-07-06 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
DE4206858A1 (de) * 1992-03-05 1993-09-09 Behringwerke Ag Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
FR2704226B1 (fr) * 1993-04-22 1995-07-21 Sanofi Elf 3-desoxy oligosaccharides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK0649854T3 (da) * 1993-09-01 2000-07-03 Akzo Nobel Nv Biskonjugater omfattende to saccharider og en spacer
IL126893A (en) * 1997-11-19 2003-05-29 Akzo Nobel Nv Sulfated pentasaccharide derivatives and pharmaceutical compositions containing them
WO1999065934A1 (en) * 1998-06-17 1999-12-23 Akzo Nobel N.V. Antithrombotic compounds

Also Published As

Publication number Publication date
EP1237897B1 (en) 2015-01-14
RU2266913C2 (ru) 2005-12-27
TWI289566B (en) 2007-11-11
PL202840B1 (pl) 2009-07-31
IL149628A0 (en) 2002-11-10
CZ303385B6 (cs) 2012-08-29
AU781846B2 (en) 2005-06-16
HUP0203471A3 (en) 2003-03-28
PE20010935A1 (es) 2001-09-20
NO20022689L (no) 2002-06-06
CA2393042C (en) 2011-06-28
CO5251449A1 (es) 2003-02-28
CN1195767C (zh) 2005-04-06
WO2001042262A3 (en) 2001-12-13
CA2393042A1 (en) 2001-06-14
SK7942002A3 (en) 2002-09-10
AR026726A1 (es) 2003-02-26
US20030114361A1 (en) 2003-06-19
PL355484A1 (en) 2004-05-04
NO20022689D0 (no) 2002-06-06
JP4820517B2 (ja) 2011-11-24
KR20020070988A (ko) 2002-09-11
KR100776607B1 (ko) 2007-11-16
HUP0203471A2 (hu) 2003-02-28
IL149628A (en) 2010-04-29
CN1407989A (zh) 2003-04-02
AU2003801A (en) 2001-06-18
SK287682B6 (sk) 2011-06-06
HK1047593A1 (zh) 2003-02-28
WO2001042262A2 (en) 2001-06-14
NZ519100A (en) 2004-09-24
JP2003520208A (ja) 2003-07-02
CZ20021958A3 (cs) 2002-08-14
NO323059B1 (no) 2006-12-27
EP1237897A2 (en) 2002-09-11
US6875755B2 (en) 2005-04-05
ZA200203799B (en) 2003-10-29

Similar Documents

Publication Publication Date Title
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BR0011324A (pt) Agonista de adrenoceptores beta 2
BR0111015A (pt) Antagonistas de receptor a2a de adenosina
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0214988A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
BR9916790A (pt) Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
BRPI0519774A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
BRPI0016395B8 (pt) derivados de adamantano
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
DK0975595T3 (da) Kokainanaloger
BR0010938A (pt) Derivados da 13-metil eritromicina
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR0016133A (pt) Composto, formulação farmacêutica, e, uso de um composto
BR0308162A (pt) Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BR0211265A (pt) Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor
BR0016130A (pt) Composto, formulação farmacêutica, e, uso de um composto
WO2001042262A3 (en) Antithrombotic compound

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AKZO NOBEL N.V. (NL) , SANOFI-SYNTHELABO (FR)

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: AKZO NOBEL N.V.

B25A Requested transfer of rights approved

Owner name: AKZO NOBEL N.V. (NL)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V. E SANOFI-SYNTHELABO

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT:CL: C07H 3/06

Ipc: C07H 3/06 (2006.01), C07H 15/26 (2006.01), A61K 31

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: MSD OSS B.V. (NL)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time